A Food and Drug Administration advisory committee is set to meetFeb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agentfor colorectal cancer developed by Immunomedics. Immunomedics,of Morris Plains, NJ, has been working with the FDA on the
A Food and Drug Administration advisory committee is set to meet
Feb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agent
for colorectal cancer developed by Immunomedics. Immunomedics,
of Morris Plains, NJ, has been working with the FDA on the agent's
product license application (PLA) since the agency said the PLA
was not approvable in 1994 (SCAN 6/1/94).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.